索拉非尼或舒尼替尼不会增加出血风险。 - Suppr

Suppr

超能文献

Risk of bleeding not increased by sorafenib or sunitinib.

作者信息

Minor David R

出版信息

Lancet Oncol. 2010 Feb;11(2):112-3; author reply 113. doi: 10.1016/S1470-2045(09)70366-3.

DOI:10.1016/S1470-2045(09)70366-3

PMID:20152763

Abstract

摘要

相似文献

Risk of bleeding not increased by sorafenib or sunitinib.

Lancet Oncol. 2010 Feb;11(2):112-3; author reply 113. doi: 10.1016/S1470-2045(09)70366-3.

Reversible cardiomyopathy associated with sunitinib and sorafenib.

N Engl J Med. 2011 Oct 27;365(17):1649-50. doi: 10.1056/NEJMc1108849.

[Cutaneous side effects of sorafenib and sunitinib].

Ann Dermatol Venereol. 2008 Feb;135(2):148-53; quiz 147, 154. doi: 10.1016/j.annder.2007.12.006. Epub 2008 Feb 13.

Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.

J Clin Oncol. 2008 Aug 20;26(24):4047-8. doi: 10.1200/JCO.2008.18.3525.

A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

J Natl Cancer Inst. 2008 Feb 20;100(4):282-4. doi: 10.1093/jnci/djm311. Epub 2008 Feb 12.

Kidney cancer: Does hypothyroidism predict clinical outcome?

Nat Rev Urol. 2011 Jan;8(1):10-1. doi: 10.1038/nrurol.2010.191. Epub 2010 Nov 30.

Sorafenib and sunitinib.

Oncologist. 2009 Aug;14(8):800-5. doi: 10.1634/theoncologist.2009-0088. Epub 2009 Aug 1.

Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?

J Clin Oncol. 2008 Nov 10;26(32):5154-5. doi: 10.1200/JCO.2008.18.5439. Epub 2008 Oct 6.

Risk of arterial thrombosis not increased by sorafenib or sunitinib.

J Clin Oncol. 2010 Oct 20;28(30):e619; author reply e620. doi: 10.1200/JCO.2010.31.0219. Epub 2010 Aug 23.

Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?

Thyroid. 2009 May;19(5):539-40. doi: 10.1089/thy.2008.0367.

引用本文的文献

Cardiotoxicity of molecularly targeted agents.

Curr Cardiol Rev. 2011 Nov;7(4):221-33. doi: 10.2174/157340311799960636.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Risk of bleeding not increased by sorafenib or sunitinib.

Lancet Oncol. 2010 Feb;11(2):112-3; author reply 113. doi: 10.1016/S1470-2045(09)70366-3.

Reversible cardiomyopathy associated with sunitinib and sorafenib.

N Engl J Med. 2011 Oct 27;365(17):1649-50. doi: 10.1056/NEJMc1108849.

[Cutaneous side effects of sorafenib and sunitinib].

Ann Dermatol Venereol. 2008 Feb;135(2):148-53; quiz 147, 154. doi: 10.1016/j.annder.2007.12.006. Epub 2008 Feb 13.

Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.

J Clin Oncol. 2008 Aug 20;26(24):4047-8. doi: 10.1200/JCO.2008.18.3525.

A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

J Natl Cancer Inst. 2008 Feb 20;100(4):282-4. doi: 10.1093/jnci/djm311. Epub 2008 Feb 12.

Kidney cancer: Does hypothyroidism predict clinical outcome?

Nat Rev Urol. 2011 Jan;8(1):10-1. doi: 10.1038/nrurol.2010.191. Epub 2010 Nov 30.

Sorafenib and sunitinib.

Oncologist. 2009 Aug;14(8):800-5. doi: 10.1634/theoncologist.2009-0088. Epub 2009 Aug 1.

Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?

J Clin Oncol. 2008 Nov 10;26(32):5154-5. doi: 10.1200/JCO.2008.18.5439. Epub 2008 Oct 6.

Risk of arterial thrombosis not increased by sorafenib or sunitinib.

J Clin Oncol. 2010 Oct 20;28(30):e619; author reply e620. doi: 10.1200/JCO.2010.31.0219. Epub 2010 Aug 23.

Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?

Thyroid. 2009 May;19(5):539-40. doi: 10.1089/thy.2008.0367.

引用本文的文献

Cardiotoxicity of molecularly targeted agents.

Curr Cardiol Rev. 2011 Nov;7(4):221-33. doi: 10.2174/157340311799960636.